Alimera Sciences, Inc. (ALIM) Downgraded to “Strong Sell” at ValuEngine

Alimera Sciences, Inc. (NASDAQ:ALIM) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Monday.

Several other equities research analysts have also recently issued reports on ALIM. Zacks Investment Research raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Tuesday, July 11th. Finally, Cowen and Company reissued a “buy” rating and set a $3.00 price target on shares of Alimera Sciences in a research report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Alimera Sciences currently has an average rating of “Hold” and an average price target of $3.38.

Shares of Alimera Sciences (NASDAQ:ALIM) traded up 2.22% during midday trading on Monday, hitting $1.38. 104,554 shares of the stock traded hands. The stock’s market cap is $95.29 million. Alimera Sciences has a 12-month low of $1.03 and a 12-month high of $1.72. The company’s 50 day moving average price is $1.43 and its 200-day moving average price is $1.43.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million for the quarter, compared to analyst estimates of $10.20 million. During the same period last year, the firm earned ($0.17) EPS. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, equities research analysts expect that Alimera Sciences will post ($0.21) EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/09/19/alimera-sciences-inc-alim-downgraded-to-strong-sell-at-valuengine.html.

Several hedge funds have recently made changes to their positions in ALIM. KCG Holdings Inc. boosted its position in shares of Alimera Sciences by 127.0% during the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 43,977 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Alimera Sciences by 24.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 35,200 shares during the last quarter. Kennedy Capital Management Inc. acquired a new position in shares of Alimera Sciences during the 1st quarter valued at about $467,000. Finally, JW Asset Management LLC boosted its position in shares of Alimera Sciences by 15.6% during the 2nd quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after acquiring an additional 130,000 shares during the last quarter. 37.20% of the stock is currently owned by hedge funds and other institutional investors.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply